WTAP and depressive symptom measurement: The present study suggested that the m6A-modifying enzyme METTL3, as well as WTAP, may play a key role in the pathogenesis and treatment of depression, which provided some hints for the development of new antidepressant drugs at the epitranscriptomic level.